SpringWorks Therapeutics (SWTX) Stock Forecast, Price Target & Predictions
SWTX Stock Forecast
SpringWorks Therapeutics stock forecast is as follows: an average price target of $67.33 (represents a 79.93% upside from SWTX’s last price of $37.42) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SWTX Price Target
The average price target for SpringWorks Therapeutics (SWTX) is $67.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $76.00 to $50.00. This represents a potential 79.93% upside from SWTX's last price of $37.42.
SWTX Analyst Ratings
According to 3 Wall Street analysts, SpringWorks Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SWTX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
SpringWorks Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Robert Burns | H.C. Wainwright | $76.00 | $33.93 | 123.99% | 103.10% |
| Aug 09, 2022 | - | H.C. Wainwright | $94.00 | $39.66 | 137.01% | 151.20% |
| May 27, 2022 | - | Wedbush | $50.00 | $18.72 | 167.09% | 33.62% |
| May 24, 2022 | - | Goldman Sachs | $76.00 | $32.74 | 132.13% | 103.10% |
The latest SpringWorks Therapeutics stock forecast, released on Aug 08, 2024 by Robert Burns from H.C. Wainwright, set a price target of $76.00, which represents a 123.99% increase from the stock price at the time of the forecast ($33.93), and a 103.10% increase from SWTX last price ($37.42).
SpringWorks Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $76.00 | $76.00 |
| Last Closing Price | $37.42 | $37.42 | $37.42 |
| Upside/Downside | -100.00% | 103.10% | 103.10% |
In the current month, the average price target of SpringWorks Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SpringWorks Therapeutics's last price of $37.42. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2022 | H.C. Wainwright | Buy | Buy | Hold |
| May 27, 2022 | Wedbush | Outperform | Outperform | Hold |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
SpringWorks Therapeutics's last stock rating was published by H.C. Wainwright on Aug 08, 2024. The company gave SWTX a "Buy" rating, the same as its previous rate.
SpringWorks Therapeutics Financial Forecast
SpringWorks Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $5.45M | - | - | $35.00M |
| Avg Forecast | $128.88M | $109.34M | $91.23M | $78.04M | $64.53M | $52.78M | $34.42M | $12.07M | $860.19K | $3.82M | $180.00 | $21.00M |
| High Forecast | $142.12M | $120.57M | $100.60M | $86.05M | $71.16M | $56.79M | $37.95M | $13.31M | $1.57M | $4.59M | $216.00 | $22.80M |
| Low Forecast | $108.26M | $91.85M | $76.63M | $65.55M | $54.21M | $45.70M | $28.91M | $10.14M | $498.36K | $3.06M | $144.00 | $17.86M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | 6.33% | - | - | 1.67% |
SpringWorks Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $12.07M, with a low forecast of $10.14M, and a high forecast of $13.31M. SWTX's average Quarter revenue forecast represents a 121.56% increase compared to the company's last Quarter revenue of $5.45M (Dec 23).
SpringWorks Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | $-97.92M | $-61.36M | $-29.68M | $11.38M |
| Avg Forecast | $-25.78M | $-21.87M | $-18.25M | $-15.61M | $-12.91M | $-10.56M | $-6.88M | $-2.41M | $-172.04K | $-47.26B | $-23.25M | $-4.20M |
| High Forecast | $-21.65M | $-18.37M | $-15.33M | $-13.11M | $-10.84M | $-9.14M | $-5.78M | $-2.03M | $-99.67K | $-37.81B | $-18.60M | $-3.57M |
| Low Forecast | $-28.42M | $-24.11M | $-20.12M | $-17.21M | $-14.23M | $-11.36M | $-7.59M | $-2.66M | $-314.04K | $-56.71B | $-27.90M | $-4.56M |
| Surprise % | - | - | - | - | - | - | - | - | 569.21% | 0.00% | 1.28% | -2.71% |
17 analysts predict SWTX's average Quarter EBITDA for Mar 21 to be $-23.25M, with a high of $-18.60M and a low of $-27.90M. This is -304.29% lower than SpringWorks Therapeutics's previous annual EBITDA (Dec 20) of $11.38M.
SpringWorks Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
| Net Income | - | - | - | - | - | - | - | - | $-94.32M | $-62.13M | $-29.79M | $11.27M |
| Avg Forecast | $-1.11M | $-17.42M | $-29.83M | $-37.99M | $-50.28M | $-55.84M | $-82.73M | $-86.86M | $-91.66M | $-47.26B | $-23.36M | $-6.18M |
| High Forecast | $-880.58K | $-13.80M | $-23.63M | $-30.09M | $-39.82M | $-44.08M | $-65.52M | $-68.79M | $-87.26M | $-37.81B | $-18.69M | $-4.97M |
| Low Forecast | $-1.26M | $-19.74M | $-33.82M | $-43.06M | $-56.99M | $-69.80M | $-93.77M | $-98.46M | $-98.26M | $-56.71B | $-28.03M | $-6.86M |
| Surprise % | - | - | - | - | - | - | - | - | 1.03% | 0.00% | 1.28% | -1.82% |
SpringWorks Therapeutics's average Quarter net income forecast for Mar 21 is $-23.36M, with a range of $-28.03M to $-18.69M. SWTX's average Quarter net income forecast represents a -307.26% decrease compared to the company's last Quarter net income of $11.27M (Dec 20).
SpringWorks Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
| SG&A | - | - | - | - | - | - | - | - | $59.84M | $27.37M | $12.38M | $8.52M |
| Avg Forecast | $1.57B | $1.33B | $1.11B | $952.06M | $787.29M | $643.93M | $419.89M | $147.23M | $10.49M | $46.65M | $2.19K | $256.19M |
| High Forecast | $1.73B | $1.47B | $1.23B | $1.05B | $868.16M | $692.88M | $463.02M | $162.36M | $19.16M | $55.98M | $2.63K | $278.13M |
| Low Forecast | $1.32B | $1.12B | $934.89M | $799.74M | $661.34M | $557.56M | $352.72M | $123.68M | $6.08M | $37.32M | $1.76K | $217.84M |
| Surprise % | - | - | - | - | - | - | - | - | 5.70% | 0.59% | 5640.55% | 0.03% |
SpringWorks Therapeutics's average Quarter SG&A projection for Mar 24 is $147.23M, based on 2 Wall Street analysts, with a range of $123.68M to $162.36M. The forecast indicates a 146.06% rise compared to SWTX last annual SG&A of $59.84M (Dec 23).
SpringWorks Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.27 | $-0.62 | $0.26 |
| Avg Forecast | $-0.01 | $-0.23 | $-0.40 | $-0.51 | $-0.68 | $-0.75 | $-1.12 | $-1.17 | $-1.24 | $-1.02 | $-0.51 | $-0.08 |
| High Forecast | $-0.01 | $-0.19 | $-0.32 | $-0.41 | $-0.54 | $-0.59 | $-0.88 | $-0.93 | $-1.18 | $-0.82 | $-0.41 | $-0.07 |
| Low Forecast | $-0.02 | $-0.27 | $-0.46 | $-0.58 | $-0.77 | $-0.94 | $-1.27 | $-1.33 | $-1.33 | $-1.14 | $-0.57 | $-0.09 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.24% | 1.22% | -3.12% |
According to 17 Wall Street analysts, SpringWorks Therapeutics's projected average Quarter EPS for Mar 21 is $-0.51, with a low estimate of $-0.57 and a high estimate of $-0.41. This represents a -296.15% decrease compared to SWTX previous annual EPS of $0.26 (Dec 20).
SpringWorks Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| SWTX | SpringWorks Therapeutics | $37.42 | $67.33 | 79.93% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
SWTX Forecast FAQ
Is SpringWorks Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, SpringWorks Therapeutics (SWTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of SWTX's total ratings.
What is SWTX's price target?
SpringWorks Therapeutics (SWTX) average price target is $67.33 with a range of $50 to $76, implying a 79.93% from its last price of $37.42. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will SpringWorks Therapeutics stock go up soon?
According to Wall Street analysts' prediction for SWTX stock, the company can go up by 79.93% (from the last price of $37.42 to the average price target of $67.33), up by 103.10% based on the highest stock price target, and up by 33.62% based on the lowest stock price target.
Can SpringWorks Therapeutics stock reach $60?
SWTX's average twelve months analyst stock price target of $67.33 supports the claim that SpringWorks Therapeutics can reach $60 in the near future.
What are SpringWorks Therapeutics's analysts' financial forecasts?
SpringWorks Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $163.8M (high $179.22M, low $138.96M), average EBITDA is $-32.761M (high $-27.792M, low $-35.844M), average net income is $-276M (high $-218M, low $-319M), average SG&A $2B (high $2.19B, low $1.7B), and average EPS is $-3.72 (high $-2.944, low $-4.304). SWTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $407.49M (high $449.34M, low $342.3M), average EBITDA is $-81.498M (high $-68.459M, low $-89.868M), average net income is $-86.351M (high $-68.391M, low $-97.881M), average SG&A $4.97B (high $5.48B, low $4.18B), and average EPS is $-1.165 (high $-0.923, low $-1.321).
Did the SWTX's actual financial results beat the analysts' financial forecasts?
Based on SpringWorks Therapeutics's last annual report (Dec 2023), the company's revenue was $5.45M, beating the average analysts forecast of $860.19K by 533.23%. Apple's EBITDA was $-343M, beating the average prediction of $-172K by 199283.27%. The company's net income was $-325M, beating the average estimation of $-91.664M by 254.67%. Apple's SG&A was $197.55M, beating the average forecast of $10.49M by 1782.50%. Lastly, the company's EPS was $-0.0052, missing the average prediction of $-1.237 by -99.58%. In terms of the last quarterly report (Dec 2023), SpringWorks Therapeutics's revenue was $5.45M, beating the average analysts' forecast of $860.19K by 533.23%. The company's EBITDA was $-97.925M, beating the average prediction of $-172K by 56820.89%. SpringWorks Therapeutics's net income was $-94.322M, beating the average estimation of $-91.664M by 2.90%. The company's SG&A was $59.84M, beating the average forecast of $10.49M by 470.19%. Lastly, the company's EPS was $0, missing the average prediction of $-1.237 by -100.00%